308.72
United Therapeutics Corp stock is traded at $308.72, with a volume of 326.01K.
It is down -0.31% in the last 24 hours and up +5.43% over the past month.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
See More
Previous Close:
$309.68
Open:
$308.25
24h Volume:
326.01K
Relative Volume:
0.65
Market Cap:
$13.93B
Revenue:
$2.99B
Net Income/Loss:
$1.21B
P/E Ratio:
12.32
EPS:
25.06
Net Cash Flow:
$1.13B
1W Performance:
+1.58%
1M Performance:
+5.43%
6M Performance:
-17.21%
1Y Performance:
+11.68%
United Therapeutics Corp Stock (UTHR) Company Profile
Name
United Therapeutics Corp
Sector
Phone
(301) 608-9292
Address
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
UTHR
United Therapeutics Corp
|
308.72 | 13.71B | 2.99B | 1.21B | 1.13B | 25.06 |
![]()
HLN
Haleon Plc Adr
|
11.06 | 48.05B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
ZTS
Zoetis Inc
|
161.97 | 71.39B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
RDHL
Redhill Biopharma Ltd Adr
|
1.85 | 3.20M | 35.75M | 11.57M | -26.25M | -3.8069 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.41 | 43.73B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.94 | 19.35B | 16.54B | -1.64B | 749.00M | -1.45 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-25-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Apr-21-25 | Upgrade | BofA Securities | Underperform → Neutral |
Jul-11-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Feb-12-24 | Upgrade | Goldman | Sell → Neutral |
Feb-05-24 | Initiated | Leerink Partners | Outperform |
Dec-08-23 | Initiated | Wells Fargo | Overweight |
Dec-06-22 | Initiated | UBS | Buy |
Dec-05-22 | Initiated | Goldman | Sell |
Oct-11-22 | Initiated | Morgan Stanley | Overweight |
Sep-20-22 | Reiterated | BofA Securities | Underperform |
Sep-19-22 | Resumed | Wedbush | Outperform |
Feb-11-22 | Initiated | BTIG Research | Neutral |
Jul-14-21 | Upgrade | Argus | Hold → Buy |
Apr-26-21 | Resumed | Credit Suisse | Outperform |
Feb-01-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
Sep-14-20 | Resumed | JP Morgan | Overweight |
Jun-25-20 | Reiterated | H.C. Wainwright | Neutral |
Mar-10-20 | Upgrade | Jefferies | Hold → Buy |
Feb-27-20 | Upgrade | Cowen | Market Perform → Outperform |
Jan-31-20 | Upgrade | JP Morgan | Neutral → Overweight |
Dec-03-19 | Initiated | BofA/Merrill | Underperform |
Aug-01-19 | Upgrade | Jefferies | Underperform → Hold |
Aug-01-19 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
Jul-01-19 | Upgrade | Credit Suisse | Neutral → Outperform |
May-17-19 | Upgrade | UBS | Sell → Neutral |
May-09-19 | Upgrade | Credit Suisse | Underperform → Neutral |
Oct-12-18 | Upgrade | Standpoint Research | Hold → Buy |
Aug-08-18 | Downgrade | Credit Suisse | Neutral → Underperform |
Apr-03-18 | Upgrade | Credit Suisse | Underperform → Neutral |
Feb-22-18 | Reiterated | Barclays | Underweight |
Jan-18-18 | Resumed | Credit Suisse | Underperform |
Dec-27-17 | Reiterated | Wedbush | Outperform |
Apr-27-17 | Reiterated | Wedbush | Outperform |
Mar-30-17 | Initiated | UBS | Sell |
Mar-16-17 | Initiated | Credit Suisse | Underperform |
View All
United Therapeutics Corp Stock (UTHR) Latest News
HHS layoffs create ‘clear opportunity’ for local health, life sciences companies to add talent - The Business Journals
Liquidia Says UTC Can’t Stop Its New Lung Drug From Launching - Bloomberg Law News
Stewartville pig-to-human transplant facility to be complete in 2026 - Post Bulletin
Interesting UTHR Put And Call Options For July 18th - Nasdaq
Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses - Yahoo Finance
UTHR Q1 Earnings Call: Double-Digit Growth Continues, Pipeline Expansion Remains Central - Yahoo Finance
UTC Again Seeks To Stave Off Lung Drug Competitor In IP Suit - Law360
Liquidia Faces Patent Litigation Filed by United Therapeutics - marketscreener.com
Liquidia (LQDA) Faces Patent Infringement Lawsuit from United Th - GuruFocus
Liquidia Says New Litigation Filed Against Co In U.S. - marketscreener.com
Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics - Yahoo Finance
Is United Therapeutics (UTHR) the Best Stock to Buy According to Jim Simons’ Renaissance Technologies? - Insider Monkey
Liquidia Corp (LQDA) Q1 2025 Earnings Call Highlights: Strategic Advances and Legal Wins Propel ... - Yahoo Finance
3 Big Reasons to Love United Therapeutics (UTHR) - Yahoo Finance
MANNKIND CORP SEC 10-Q Report - TradingView
Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update - Yahoo Finance
TD Cowen maintains United Therapeutics stock Buy rating By Investing.com - Investing.com Nigeria
TD Cowen maintains United Therapeutics stock Buy rating - Investing.com
3 Market-Beating Stocks with Solid Fundamentals - Yahoo Finance
United Therapeutics (UTHR) Target Price Lowered by Argus, Retains Buy Rating | UTHR Stock News - GuruFocus
Liquidia Fends Off Indication Challenge In UTC Tyvaso Fight - Law360
United Therapeutics (UTHR) Receives Reiterated "Buy" Rating from HC Wainwright | UTHR Stock News - GuruFocus
Liquidia Corporation: A Strong Buy On High Likelihood Of FDA Approval This Month - Seeking Alpha
District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia - GlobeNewswire Inc.
US judge dismisses United Therapeutics' counterclaims over Liquidia's 'Yutrepia' - MLex
United Therapeutics (UTHR) Gets a Hold from Wells Fargo - The Globe and Mail
Legal Victory: Liquidia Clears Major Hurdle for YUTREPIA Dual-Indication Approval This Month - Stock Titan
BofA raises United Therapeutics stock target to $321 - Investing.com Australia
United Therapeutics (UTHR): Morgan Stanley Raises Price Target | - GuruFocus
BofA raises United Therapeutics stock target to $321 By Investing.com - Investing.com Canada
United Therapeutics (UTHR) Analyst Update: JP Morgan Maintains R - GuruFocus
United Therapeutics (UTHR) Analyst Update: JP Morgan Maintains Rating | UTHR Stock News - GuruFocus
United Therapeutics (UTHR): Morgan Stanley Raises Price Target | UTHR Stock News - GuruFocus
Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insig - GuruFocus
United Therapeutics Corporation (NASDAQ:UTHR) Q1 2025 Earnings Call Transcript - Insider Monkey
Avepoint, Meta, United Therapeutics - TradingView
United Therapeutics: Q1 Earnings Snapshot - New Haven Register
United Therapeutics Corp (UTHR) Q1 2025 Earnings Call Highlights: Record Revenue and Strategic ... - Yahoo Finance
United Therapeutics Reports Strong Q1 2025 Growth - TipRanks
United Therapeutics Corp. Reports Record Revenue Growth - TipRanks
Earnings call transcript: United Therapeutics Q1 2025 beats expectations - Investing.com
United Therapeutics Corp Surpasses Q1 2025 Estimates with $7.18 EPS and $794.4 Million Revenue - GuruFocus
United Therapeutics (UTHR) Surpasses Q1 Earnings Expectations - GuruFocus
United Therapeutics beats Q1 estimates, shares edge higher - Investing.com
United Therapeutics Q1 Earnings, Revenue Rise - marketscreener.com
United Therapeutics Q1 2025 slides: revenue jumps 17%, organ transplant milestone nears - Investing.com
United Therapeutics Corporation Reports First Quarter 2025 Financial Results - TradingView
UNITED THERAPEUTICS Corp SEC 10-Q Report - TradingView
United Therapeutics Corp Stock (UTHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):